진원생명과학

011000KOSPI의약품 제조업

46.9 / 100

Reference Date: 2026-07-24

Financial Score7.5 / 40

News Sentiment14.4 / 25

Momentum15.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Surged 400.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Jinwon Pharmaceuticals focuses on biopharmaceutical CDMO services and next-generation biopharmaceutical development. The CDMO business produces cGMP-grade plasmid DNA for gene therapies and DNA vaccines, while also advancing mRNA vaccine and therapeutic development through technology licensing. In new drug development, the company has completed clinical trials for DNA vaccines targeting MERS, Zika, and SFTS, and is expanding research through global partnerships.

Number of Employees

52people

Average Salary

70.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

1.19Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE

-81.98Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

59.91Industry Average 12.430.0Point

4.8x industry avg (risky)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼23.3% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -61.4% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 1Average Sentiment Score 57.5

Neutral
오늘의 메모[7월 21일]
The news includes unrelated stock activities affecting multiple companies across different exchanges, with no direct impact on 진원생명과학(011000).
Negative
“퇴출될라”…상폐 압박에 바이오·헬스 기업 생존 몸부림
바이오 및 헬스케어 기업들의 주식 병합과 CB 전환가 조정으로 인해 진원생명과학의 주가 하락과 주주 불만이 증가하고 있다.

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 2,670Won52-week high 2,67052-week low 534

1-month return6.0Point

1m +400.00% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral기타시장안내 (상장적격성 실질심사 사유 발생)2026-07-16
Neutral투자판단관련주요경영사항2026-07-16
Neutral조회공시요구(풍문또는보도)2026-07-15
Neutral매매거래정지및정지해제(풍문등조회공시)2026-07-15
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-29